Ruchika Pokhriyal

Ruchika Pokhriyal

Auto-generated profile, based on publicly available information

Ruchika Pokhriyal

Department of Biophysics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Biomarkers in Cancer
Verified
Journal Article
Open access
USUrmila Sehrawat
Urmila Sehrawat
RPRuchika Pokhriyal
Ruchika Pokhriyal
AGAshish Kumar Gupta
Ashish Kumar Gupta
RHRoopa Hariprasad
Roopa Hariprasad
MKMohd Imran Khan
Mohd Imran Khan
GHGururao Hariprasad
Gururao Hariprasad
Conventional treatment for advanced ovarian cancer is an initial debulking surgery followed by chemotherapy combination of carboplatin and paclitaxel. Despite initial high response, three-fourths of these women experience disease recurrence with a dismal prognosis. Patients with advanced-stage ovarian cancer who underwent cytoreductive surgery were enrolled and tissue samples were collected. Post surgery, these patients were started on chemotherapy and followed up till the end of the cycle. Fluorescence-based differential in-gel expression coupled with mass spectrometric analysis was used for discovery phase of experiments, and real-time polymerase chain reaction, Western blotting, and pathway analysis were performed for expression and functional validation of differentially expressed proteins. While aldehyde reductase, hnRNP, cyclophilin A, heat shock protein-27, and actin are upregulated in responders, prohibitin, enoyl-coA hydratase, peroxiredoxin, and fibrin-β are upregulated in the nonresponders. The expressions of some of these proteins correlated with increased apoptotic activity in responders and decreased apoptotic activity in nonresponders. Therefore, the proteins qualify as potential biomarkers to predict chemotherapy response.